Rogers Campbell 4
4 · Heartflow, Inc. · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Heartflow (HTFL) CMO Rogers Campbell Exercises Options, Sells Shares
What Happened
Rogers Campbell, Chief Medical Officer of Heartflow (HTFL), exercised stock options and sold shares on February 12, 2026. The filing shows exercises that resulted in acquisition of 67,016 shares at aggregate strike cost of $391,397 (breakouts: 19,401 @ $2.22 = $43,070; 39,709 @ $8.33 = $330,776; 7,906 @ $2.22 = $17,551). On the same date he sold 65,153 shares in an open-market transaction for a weighted-average price of $24.49, generating proceeds of approximately $1,595,486. The sale included 17,538 shares previously held and the exercise-and-sale of 47,615 shares under the reported 10b5-1 plan.
This transaction is primarily a sale (liquidation of shares after option exercise), which many insiders use for liquidity or tax purposes. The exercises (transaction code M) and sale (code S) were effected pursuant to a Rule 10b5-1 trading plan.
Key Details
- Transaction date: February 12, 2026 (reported on Form 4 filed Feb 17, 2026). The filing appears timely.
- Shares exercised (acquired): 67,016 total — 19,401 @ $2.22; 39,709 @ $8.33; 7,906 @ $2.22 (total strike cost ~$391,397).
- Shares sold (disposed): 65,153 @ weighted-average $24.49 for ~$1,595,486. Reported trade prices ranged from $22.90 to $26.51 (weighted average shown).
- Breakdown of sale: 17,538 previously held shares + 47,615 shares from option exercise were sold under the plan.
- Footnotes of note:
- Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted Sept 12, 2025 (F1, F2, F3).
- Some options are fully exercisable (F5); others vest in monthly installments through July 1, 2027 (F6).
- Multiple trades executed at various prices; weighted average reported (F4).
- Shares owned after the transactions: not specified in the provided excerpt of the filing.
Context
- For retail investors: an insider exercising options and immediately selling most of the resulting shares is commonly a liquidity/tax-management move rather than a clear bullish signal. Purchases are usually more informative about insider conviction than routine sell-to-cover or exercise-and-sell transactions.
- Technical note: Transaction code M = option exercise/conversion; S = sale. Some derivative entries appear with $0 amounts because they reflect conversion/transfer of option interests rather than a cash sale.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-12$2.22/sh+19,401$43,070→ 93,572 total - Exercise/Conversion
Common Stock
[F2]2026-02-12$8.33/sh+39,709$330,776→ 133,281 total - Exercise/Conversion
Common Stock
[F2]2026-02-12$2.22/sh+7,906$17,551→ 141,187 total - Sale
Common Stock
[F3][F4]2026-02-12$24.49/sh−65,153$1,595,486→ 76,034 total - Exercise/Conversion
Stock Option
[F2][F5]2026-02-12−39,709→ 0 totalExercise: $8.33Exp: 2026-03-09→ Common Stock (39,709 underlying) - Exercise/Conversion
Stock Option
[F1][F6]2026-02-12−19,401→ 216,433 totalExercise: $2.22Exp: 2033-07-10→ Common Stock (19,401 underlying) - Exercise/Conversion
Stock Option
[F2][F6]2026-02-12−7,906→ 208,527 totalExercise: $2.22Exp: 2033-07-10→ Common Stock (7,906 underlying)
- 22,615(indirect: By Trust)
Common Stock
- 46,159(indirect: By Trust)
Common Stock
- 26,012(indirect: By Trust)
Common Stock
- 50,754(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- [F2]The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- [F3]Includes the sale of 17,538 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- [F4]This transaction was executed in multiple trades at price ranging from $22.90 to $26.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]These stock options are fully exercisable.
- [F6]The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.